12 Participants Needed

ABA-101 for Multiple Sclerosis

Recruiting at 2 trial locations
AO
SW
LD
Overseen ByLeonard Dragone, MD PhD
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)
Approved in 1 JurisdictionThis treatment is already approved in other countries

Trial Summary

What is the purpose of this trial?

This study will test the safety and effects of ABA-101 when given as a single dose to participants with progressive multiple sclerosis. It is the first study of this treatment in humans. After safety is demonstrated with a low dose of ABA-101, a higher dose will be evaluated.

Will I have to stop taking my current medications?

The trial requires that participants are not currently on disease-modifying therapies (DMTs), so you would need to stop taking those medications to join.

Eligibility Criteria

This trial is for adults over 18 with progressive multiple sclerosis, confirmed by the McDonald criteria. Participants must show signs of brain inflammation on MRI, have worsening disability not linked to MS relapses, match a specific genetic marker (HLA), and meet certain physical function tests.

Inclusion Criteria

I can complete the nine-hole peg test as required.
My MS is getting worse without having relapses.
Has a diagnosis of MS per the 2017 revised McDonald criteria
See 3 more

Exclusion Criteria

Is considered by the Investigator to be immunocompromised
I am currently on medication to slow my disease's progression.
My condition worsened or returned within the last 24 months.

Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive a single ascending dose of ABA-101, starting with a low dose followed by a high dose after safety is demonstrated

1 day
1 visit (in-person)

Follow-up

Participants are monitored for safety and effectiveness after treatment, with adverse events tracked through Day 29

4 weeks

Treatment Details

Interventions

  • ABA-101
Trial Overview The study is testing ABA-101's safety and effects in humans for the first time. It starts with a low dose to ensure safety before moving on to higher doses in participants with progressive MS.
Participant Groups
2Treatment groups
Experimental Treatment
Group I: ABA-101 Dose 2Experimental Treatment1 Intervention
High Dose ABA-101
Group II: ABA-101 Dose 1Experimental Treatment1 Intervention
Low Dose ABA-101

ABA-101 is already approved in United States for the following indications:

๐Ÿ‡บ๐Ÿ‡ธ
Approved in United States as ABA-101 for:
  • Progressive Multiple Sclerosis (under investigation, not approved)

Find a Clinic Near You

Who Is Running the Clinical Trial?

Abata Therapeutics

Lead Sponsor

Trials
1
Recruited
10+
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top
Terms of ServiceยทPrivacy PolicyยทCookiesยทSecurity